Glycated albumin in diabetic patients with chronic kidney disease

Cai Mei Zheng, Wen Ya Ma, Chia Chao Wu, Kuo Cheng Lu

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine. In current clinical practice, long-term glycemic control is assessed by quarterly measurements of HbA1c. Since the degree of hemoglobin glycosylation depends not only on the level of glycemic control, but also on the lifespan of red blood cells, patients with hemoglobin disorders or anemia of any cause may have erroneous HbA1c levels, and consequently receive insufficient treatment. Patients with chronic kidney disease (CKD) often suffer from various types of anemia, and consequently, they are frequently treated with iron and/or erythropoietin therapy or frequent blood transfusion. Thus, serum GA is a potentially useful glycemic index in diabetic patients with CKD, since it is not influenced by anemia and associated treatments. GA may also reflect the status of blood glucose more rapidly (2-3. weeks) than HbA1c (2-3. months), and is beneficial in those with wide variations in blood glucose or at higher risk for hypoglycemia. If clinical investigations support its utility, it may be applicable as a screening tool for all patients with diabetes during routine health examinations. Serum GA levels are also associated with AGE-related fluorescence and the number of glycation sites, and it may influence the structural and functional changes inalbumin. Since end-stage renal disease is an extreme microvascular complication of diabetic nephropathy, CKD patients with diabetes should be carefully managed to prevent disease progression. In this review, the clinical aspects of GA were discussed, including a comparison of GA with other glycated proteins, the utility and limitations of GA as a glycemic index, its influence on the therapeutic effects of hypoglycemic agents, its correlations with vascular complications, and its potential role in pathogenesis, specifically in diabetic patients with CKD.

Original languageEnglish
Pages (from-to)1555-1561
Number of pages7
JournalClinica Chimica Acta
Volume413
Issue number19-20
DOIs
Publication statusPublished - Oct 9 2012

Fingerprint

Chronic Renal Insufficiency
Glycemic Index
Anemia
Medical problems
Serum Albumin
Blood Glucose
Hemoglobins
Blood
Fructosamine
Glycosylation
Glycosylated Hemoglobin A
Diabetic Nephropathies
Therapeutic Uses
Erythropoietin
glycosylated serum albumin
Hypoglycemia
Hypoglycemic Agents
Blood Transfusion
Hyperglycemia
Chronic Kidney Failure

Keywords

  • Amadori reaction
  • Chronic kidney disease
  • Diabetes
  • Glycated albumin
  • Glycated hemoglobin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Glycated albumin in diabetic patients with chronic kidney disease. / Zheng, Cai Mei; Ma, Wen Ya; Wu, Chia Chao; Lu, Kuo Cheng.

In: Clinica Chimica Acta, Vol. 413, No. 19-20, 09.10.2012, p. 1555-1561.

Research output: Contribution to journalArticle

Zheng, Cai Mei ; Ma, Wen Ya ; Wu, Chia Chao ; Lu, Kuo Cheng. / Glycated albumin in diabetic patients with chronic kidney disease. In: Clinica Chimica Acta. 2012 ; Vol. 413, No. 19-20. pp. 1555-1561.
@article{c50c35d4fbdc414b94629895cf3507d6,
title = "Glycated albumin in diabetic patients with chronic kidney disease",
abstract = "Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine. In current clinical practice, long-term glycemic control is assessed by quarterly measurements of HbA1c. Since the degree of hemoglobin glycosylation depends not only on the level of glycemic control, but also on the lifespan of red blood cells, patients with hemoglobin disorders or anemia of any cause may have erroneous HbA1c levels, and consequently receive insufficient treatment. Patients with chronic kidney disease (CKD) often suffer from various types of anemia, and consequently, they are frequently treated with iron and/or erythropoietin therapy or frequent blood transfusion. Thus, serum GA is a potentially useful glycemic index in diabetic patients with CKD, since it is not influenced by anemia and associated treatments. GA may also reflect the status of blood glucose more rapidly (2-3. weeks) than HbA1c (2-3. months), and is beneficial in those with wide variations in blood glucose or at higher risk for hypoglycemia. If clinical investigations support its utility, it may be applicable as a screening tool for all patients with diabetes during routine health examinations. Serum GA levels are also associated with AGE-related fluorescence and the number of glycation sites, and it may influence the structural and functional changes inalbumin. Since end-stage renal disease is an extreme microvascular complication of diabetic nephropathy, CKD patients with diabetes should be carefully managed to prevent disease progression. In this review, the clinical aspects of GA were discussed, including a comparison of GA with other glycated proteins, the utility and limitations of GA as a glycemic index, its influence on the therapeutic effects of hypoglycemic agents, its correlations with vascular complications, and its potential role in pathogenesis, specifically in diabetic patients with CKD.",
keywords = "Amadori reaction, Chronic kidney disease, Diabetes, Glycated albumin, Glycated hemoglobin",
author = "Zheng, {Cai Mei} and Ma, {Wen Ya} and Wu, {Chia Chao} and Lu, {Kuo Cheng}",
year = "2012",
month = "10",
day = "9",
doi = "10.1016/j.cca.2012.04.025",
language = "English",
volume = "413",
pages = "1555--1561",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "19-20",

}

TY - JOUR

T1 - Glycated albumin in diabetic patients with chronic kidney disease

AU - Zheng, Cai Mei

AU - Ma, Wen Ya

AU - Wu, Chia Chao

AU - Lu, Kuo Cheng

PY - 2012/10/9

Y1 - 2012/10/9

N2 - Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine. In current clinical practice, long-term glycemic control is assessed by quarterly measurements of HbA1c. Since the degree of hemoglobin glycosylation depends not only on the level of glycemic control, but also on the lifespan of red blood cells, patients with hemoglobin disorders or anemia of any cause may have erroneous HbA1c levels, and consequently receive insufficient treatment. Patients with chronic kidney disease (CKD) often suffer from various types of anemia, and consequently, they are frequently treated with iron and/or erythropoietin therapy or frequent blood transfusion. Thus, serum GA is a potentially useful glycemic index in diabetic patients with CKD, since it is not influenced by anemia and associated treatments. GA may also reflect the status of blood glucose more rapidly (2-3. weeks) than HbA1c (2-3. months), and is beneficial in those with wide variations in blood glucose or at higher risk for hypoglycemia. If clinical investigations support its utility, it may be applicable as a screening tool for all patients with diabetes during routine health examinations. Serum GA levels are also associated with AGE-related fluorescence and the number of glycation sites, and it may influence the structural and functional changes inalbumin. Since end-stage renal disease is an extreme microvascular complication of diabetic nephropathy, CKD patients with diabetes should be carefully managed to prevent disease progression. In this review, the clinical aspects of GA were discussed, including a comparison of GA with other glycated proteins, the utility and limitations of GA as a glycemic index, its influence on the therapeutic effects of hypoglycemic agents, its correlations with vascular complications, and its potential role in pathogenesis, specifically in diabetic patients with CKD.

AB - Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine. In current clinical practice, long-term glycemic control is assessed by quarterly measurements of HbA1c. Since the degree of hemoglobin glycosylation depends not only on the level of glycemic control, but also on the lifespan of red blood cells, patients with hemoglobin disorders or anemia of any cause may have erroneous HbA1c levels, and consequently receive insufficient treatment. Patients with chronic kidney disease (CKD) often suffer from various types of anemia, and consequently, they are frequently treated with iron and/or erythropoietin therapy or frequent blood transfusion. Thus, serum GA is a potentially useful glycemic index in diabetic patients with CKD, since it is not influenced by anemia and associated treatments. GA may also reflect the status of blood glucose more rapidly (2-3. weeks) than HbA1c (2-3. months), and is beneficial in those with wide variations in blood glucose or at higher risk for hypoglycemia. If clinical investigations support its utility, it may be applicable as a screening tool for all patients with diabetes during routine health examinations. Serum GA levels are also associated with AGE-related fluorescence and the number of glycation sites, and it may influence the structural and functional changes inalbumin. Since end-stage renal disease is an extreme microvascular complication of diabetic nephropathy, CKD patients with diabetes should be carefully managed to prevent disease progression. In this review, the clinical aspects of GA were discussed, including a comparison of GA with other glycated proteins, the utility and limitations of GA as a glycemic index, its influence on the therapeutic effects of hypoglycemic agents, its correlations with vascular complications, and its potential role in pathogenesis, specifically in diabetic patients with CKD.

KW - Amadori reaction

KW - Chronic kidney disease

KW - Diabetes

KW - Glycated albumin

KW - Glycated hemoglobin

UR - http://www.scopus.com/inward/record.url?scp=84864383134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864383134&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2012.04.025

DO - 10.1016/j.cca.2012.04.025

M3 - Article

C2 - 22579765

AN - SCOPUS:84864383134

VL - 413

SP - 1555

EP - 1561

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 19-20

ER -